Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion

Frontiers in Surgery

Jaswinder S. Samra²  Anthony J. Gill³  Anubhav Mittal⁴  Matthew Wong⁶  Samriti Sood⁷  Amanda Stevanovic⁸  Connie I. Diakos⁹  Danika Zuidersma^1,10  Adam Ofri^1,12 

[1] 0Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia;1School of Medicine, Macquarie University, Sydney, Australia;2NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia;3School of Medicine, University of Notre Dame, Sydney, Australia;Australian Pancreatic Centre, St Leonards, Sydney, Australia;Central Coast Cancer Centre, Gosford Hospital, Gosford, Australia;Department of Breast Surgery, Royal North Shore Hospital, St Leonards, Australia;Department of Medical Oncology, Nepean Cancer Care Centre, Nepean, Australia;Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia;Department of Surgery, Sir Charles Gairdner Hospital, Nedlands, Australia;Kolling Institute of Medical Research, University of Sydney, Sydney, Australia;St Vincent’s Clinical School, University of New South Wales, Sydney, Australia;Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, St Leonards,Australia;

关键词: pancreatic cancer;    breast cancer;    synchronous;    non-germline;    neoadjuvant treatment;   

DOI  :  10.3389/fsurg.2022.858349

来源: DOAJ

【 摘 要 】

BackgroundSynchronous cancers are rarely detected when working-up a patient for a primary cancer. Neoadjuvant management of synchronous breast and pancreatic cancers, without a germline mutation, has yet to be discussed. Two patients were diagnosed with synchronous breast and pancreatic cancers at our institution over the last decade. A literature review was performed to evaluate the current evidence stance.ResultsThe first patient was 61-years old and diagnosed with a HER2+ breast cancer. The second patient was 77-years old and diagnosed with a Luminal B breast cancer. The inability to provide concurrent breast and pancreatic neoadjuvant therapy for the HER2+ patient, resulted in upfront surgery. The second patient was able to have both cancers treated simultaneously - neoadjuvant chemotherapy to the pancreas, and neoadjuvant endocrine therapy to the breast.DiscussThere is no single neoadjuvant regimen that treats both pancreatic and breast cancer. The differences in breast cancer sub-types impacted our neoadjuvant options. Our recent experience led us to the hypothesis that breast cancer care dictates treatment, while pancreatic cancer determines survival. There is a significant paucity in the literature regarding synchronous breast and pancreatic cancer.

【 授权许可】

Unknown